Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Pre-TURBT mitomycin-C improves RFS in NMIBC
26 Mar 2026
bởiAudrey Abella
In the updated 5-year analysis of a randomized phase II trial, administering two doses of intravesical mitomycin-C (MMC) immediately before transurethral resection of bladder tumour (TURBT) improves recurrence-free survival (RFS) in individuals with non-muscle invasive bladder cancer (NMIBC).
26 Mar 2026







